Systemic capillary leak syndrome (SCLS) is a syndrome caused by many reasons and without a definitive mechanism. The main diagnostic criteria of SCLS are hemoconcentration, hypoalbuminemia, and hypotension. Though most SCLS improved spontaneously within a few days, it can be life-threatening without effective treatments. In previous literature, vascular endothelial growth factor (VEGF) inhibitor had shown its potential to be an effective treatment, but the treatment outcomes were inconsistent. This article was about a 58-year-old female suffering from refractory systemic capillary leak syndrome after bone marrow transplantation and being treated with bevacizumab, a VEGF inhibitor. In comparison with other successfully treated cases, this patient received four cycles of bevacizumab treatment without symptomatic improvement and eventually died in the intensive care unit. Further studies are needed to further confirm the role of bevacizumab in the management of SCLS.

全身性毛细血管渗漏综合征（SCLS）是一种由多种原因引起的综合征，没有明确的机制。SCLS的主要诊断标准是血液浓缩、低白蛋白血症和低血压。虽然大多数 SCLS 在几天内自发改善，但如果没有有效的治疗，它可能会危及生命。在以往的文献中，血管内皮生长因子（VEGF）抑制剂已显示出其潜在的有效治疗方法，但治疗结果并不一致。这篇文章是关于一名 58 岁的女性在骨髓移植后患有难治性全身毛细血管渗漏综合征，并正在接受 VEGF 抑制剂贝伐单抗治疗。与其他成功治疗的病例相比，该患者接受了四个周期的贝伐单抗治疗，症状没有改善，最终死于重症监护室。需要进一步的研究来进一步证实贝伐单抗在 SCLS 治疗中的作用。